Clinical Trial: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155668) titled 'A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)' on Aug. 07.

Brief Summary: This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Thyroid Eye Disease

Intervention: DRUG: VRDN-003

VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

DEVICE: Autoinjector

The autoinjector is a single-...